Opinions
Jim Cramer - Mad Money
Axsome Therapeutics
AXSM-Q
RISKY
Feb 05, 2024
$91.450
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
They make drugs to treat the central nervous system, an area that rarely sees success. However, their drug pipeline looks promising. Their lead depression drug is in phase 3 trials, in early trials for smoking cessation, a migraine drug, and one for muscle weakness caused by narcolepsy. If all goes right, this stock could triple. Overall, the market is getting more interested in biotechs, and two analysts just started coverage (buy and outperform) on AXSM, based on their pipeline and cash flow. Last month, they pre-announced positive sales on two key drugs.